Age, obesity and hyperglycemia but not ethanol intake are the main risk factors for developing fatty liver in men

Parés, Antonia; Tresserras, Ricard; Núñez, Iria; Carrasco, José Luís; Caballería, Llorenç; Bru, C.; Caballería, Joan; Salleras, L.; Rodés, Juan

doi:10.1016/s0168-8278(00)81131-9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once viral infection has been excluded, the majority of these subjects are described as having "fatty liver" [43], an entity that has become the most frequent hepatopathy in the Western World and, probably, in Spain as well [44,45]. Indeed, the condition has reached a prevalence of 13.8% according to a work-place study conducted with 1713 Spanish males aged between 18 and 60 years; prevalence was reduced to 8.8% when obese and diabetic subjects ere excluded form the analyses [46]. Further, non-alcoholic fatty liver or non-alcoholic fatty liver disease (NAFLD) was clearly associated with abdominal obesity, dyslipemia and diabetes mellitus, all of what are risk factors for atherosclerosis [47].…”

Section: Asymptomatic Hypertransaminasemiamentioning

confidence: 99%

Statins: Hepatic Disease and Hepatotoxicity Risk

Cueto¹,

Valdivielso²,

Lucena³

et al. 2008

TOGASJ

View full text Add to dashboard Cite

Abstract:The hydroxy-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors generally have a good safety profile and are one of the most prescribed drugs in Europe. Nevertheless, differences in physicochemical and pharmacokinetic properties statins may translate into relevant differences in long term safety. In clinical trials, all lipid-lowering agents have been associated with mild asymptomatic elevation of aminotransferase enzymes. Studies that evaluate the risk of hepatotoxicity from statins in hyperlipidemic subjects with elevated baseline serum transaminases are lacking and furthermore, statins are considered contraindicated in patients with chronic liver disease. However, clinical and biochemical monitoring is routinely recommended or required, often to make up for the lack of information on the true risk of clinically significant liver toxicity of these agents in individuals both with and without underlying liver disease although there is no evidence that monitoring reduces the rate of hepatotoxicity. This article will review what is and what is not known about hepatic disease and hepatotoxicity risk due to the statins and offers recommendations for the safe and rational use of this group of drugs in the setting of specials situations.

show abstract